JW Cayman Therapeutics publishes 2025 annual report

PUBT · 1d ago
JW Cayman Therapeutics publishes 2025 annual report
  • JW Cayman Therapeutics annual report for 2025 flagged continued commercialization momentum for Carteyva, supported by broader insurance coverage across China.
  • Regulatory work advanced for Carteyva expansion into second-line use for transplant-ineligible r/r LBCL, with sNDA accepted for review in May 2025.
  • Manufacturing strategy shifted toward in-house lentiviral vector supply for Carteyva, with post-approval submission accepted in 2025 to support cost reduction.
  • Pipeline execution extended beyond hematology, with relma-cel SLE Phase I data submitted to NMPA in October 2025.
  • Partnership activity increased, with Juno licensing JW lentiviral vector manufacturing process in April 2025; Regeneron amended collaboration in October 2025 to fund MAGE-A4 program and license JW drug product process.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12127043), on April 28, 2026, and is solely responsible for the information contained therein.